156 related articles for article (PubMed ID: 17374707)
41. Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies.
Smith ER; Ford ML; Tomlinson LA; Weaving G; Rocks BF; Rajkumar C; Holt SG
Clin Chim Acta; 2011 May; 412(11-12):1008-11. PubMed ID: 21324311
[TBL] [Abstract][Full Text] [Related]
42. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays.
Durham BH; Joseph F; Bailey LM; Fraser WD
Ann Clin Biochem; 2007 Sep; 44(Pt 5):463-6. PubMed ID: 17761032
[TBL] [Abstract][Full Text] [Related]
43. Tumor-induced osteomalacia: lessons learned.
Lewiecki EM; Urig EJ; Williams RC
Arthritis Rheum; 2008 Mar; 58(3):773-7. PubMed ID: 18311810
[TBL] [Abstract][Full Text] [Related]
44. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling.
van Boekel G; Ruinemans-Koerts J; Joosten F; Dijkhuizen P; van Sorge A; de Boer H
Eur J Endocrinol; 2008 Mar; 158(3):431-7. PubMed ID: 18299479
[TBL] [Abstract][Full Text] [Related]
45. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
46. Tumor-induced osteomalacia and symptomatic looser zones secondary to mesenchymal chondrosarcoma.
Zura RD; Minasi JS; Kahler DM
J Surg Oncol; 1999 May; 71(1):58-62. PubMed ID: 10362094
[TBL] [Abstract][Full Text] [Related]
47. Tumor induced osteomalacia.
Ioakimidis DE; Dendrinos GK; Frangia KB; Babiolakis DN; Chilas GI; Lyberopoulos KL; Kontomerkos TK
J Rheumatol; 1994 Jun; 21(6):1162-4. PubMed ID: 7932437
[TBL] [Abstract][Full Text] [Related]
48. Effect of a 300 000-IU loading dose of ergocalciferol (Vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency.
Turner C; Dalton N; Inaoui R; Fogelman I; Fraser WD; Hampson G
J Clin Endocrinol Metab; 2013 Feb; 98(2):550-6. PubMed ID: 23284004
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia.
Larsson T; Zahradnik R; Lavigne J; Ljunggren O; Jüppner H; Jonsson KB
Eur J Endocrinol; 2003 Feb; 148(2):269-76. PubMed ID: 12590648
[TBL] [Abstract][Full Text] [Related]
50. Lower serum fibroblast growth factor-23 levels may suggest malnutrition in maintenance haemodialysis patients.
Mizuiri S; Nishizawa Y; Yamashita K; Ono K; Oda M; Usui K; Shigemoto K
Nephrology (Carlton); 2014 Sep; 19(9):568-73. PubMed ID: 24947687
[TBL] [Abstract][Full Text] [Related]
51. Novel regulators of phosphate homeostasis and bone metabolism.
Jüppner H
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S3-22. PubMed ID: 17976082
[TBL] [Abstract][Full Text] [Related]
52. Tumor-induced osteomalacia: The tumor may stay hidden!
van der Rest C; Cavalier E; Kaux JF; Krzesinski JM; Hustinx R; Reginster JY; Delanaye P
Clin Biochem; 2011 Oct; 44(14-15):1264-6. PubMed ID: 21843522
[TBL] [Abstract][Full Text] [Related]
53. Oncogenic osteomalacia associated with soft tissue chondromyxoid fibroma.
Park JM; Woo YK; Kang MI; Kang CS; Hahn ST
Eur J Radiol; 2001 Aug; 39(2):69-72. PubMed ID: 11522411
[TBL] [Abstract][Full Text] [Related]
54. Phosphaturic mesenchymal tumor: An underdiagnosed rare entity.
Patra S; Trivedi P; Jhaveri C
Indian J Pathol Microbiol; 2022; 65(1):181-183. PubMed ID: 35074991
[TBL] [Abstract][Full Text] [Related]
55. Oncogenous osteomalacia.
Ghosh S; Sinha R; Bandyopadhyay R; Malhotra M
J Cancer Res Ther; 2009; 5(3):210-2. PubMed ID: 19841566
[TBL] [Abstract][Full Text] [Related]
56. Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels.
Halperin F; Anderson RJ; Mulder JE
Nat Clin Pract Endocrinol Metab; 2007 Oct; 3(10):721-5. PubMed ID: 17893691
[TBL] [Abstract][Full Text] [Related]
57. Hypophosphatemic osteomalacia secondary to neoplasia.
Cotton GE; Van Puffelen P
J Bone Joint Surg Am; 1986 Jan; 68(1):129-33. PubMed ID: 3001095
[No Abstract] [Full Text] [Related]
58. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).
Houang M; Clarkson A; Sioson L; Elston MS; Clifton-Bligh RJ; Dray M; Ranchere-Vince D; Decouvelaere AV; de la Fouchardiere A; Gill AJ
Hum Pathol; 2013 Dec; 44(12):2711-8. PubMed ID: 24060005
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients.
Fassbender WJ; Brandenburg V; Schmitz S; Sandig D; Simon SA; Windolf J; Stumpf UC
Clin Lab; 2009; 55(3-4):144-52. PubMed ID: 19462937
[TBL] [Abstract][Full Text] [Related]
60. [FGF-23].
Miyauchi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():378-84. PubMed ID: 15035156
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
